There is substantial inter-individual variability in serum testosterone levels in hypogonadal men treated with testosterone gels. We aimed to elucidate participant-level factors that contribute to inter-individual variability in testosterone levels during testosterone therapy. An exploratory aim was to determine whether polymorphisms in genes encoding testosterone-metabolizing enzymes could explain the variation in on-treatment testosterone concentrations in men who were randomized to testosterone arm in TOM Trial. We used data from three randomized trials that used 1% transdermal testosterone gels and had testosterone levels measured 2-4 weeks after randomization for dose adjustment: Testosterone in Older Men with Mobility Limitation (TOM), Effects of Testosterone on Pain Perception (TAP), and Effects of Testosterone on Atherosclerosis Progression (TEAAM). Forty-seven percent, 38%, and 9% of participants in TAP, TEAAM, and TOM trials, respectively, failed to raise testosterone levels >400 ng/dL; 6, 8, and 30% of participants had on-treatment testosterone levels >1000 ng/dL. Even after dose adjustment, there was substantial variation in on-treatment levels at subsequent study visits. Baseline characteristics (age, height, weight, baseline testosterone, SHBG, hematocrit, and creatinine) accounted for only a small fraction of the variance (<8%). Polymorphisms in SHBG and AKR1C3 genes were suggestively associated with on-treatment testosterone levels. To conclude, baseline participant characteristics account for only a small fraction of the variance in on-treatment testosterone levels investigated. Multiple dose titrations are needed to maintain on-treatment testosterone levels in the target range. The role of SHBG and AKR3C1 polymorphisms as contributors to variations in on-treatment testosterone levels should be investigated.
INTRODUCTION
Testosterone therapy is indicated for the treatment of men with androgen deficiency syndromes and aims to induce and maintain secondary sex characteristics and to improve sexual function, energy, and bone mineral density (Wang et al., 2009; Bhasin et al., 2010) . A number of testosterone formulations have been approved for the treatment of hypogonadism in men, including injectable testosterone esters, testosterone transdermal patch, transdermal testosterone gels and solution, buccal adhesive testosterone tablets, intranasal testosterone, and testosterone pellets (Snyder & Lawrence, 1980; Meikle et al., 1996; Wang et al., 2000 Wang et al., , 2009 Wang et al., , 2011 Bhasin et al., 2001 Bhasin et al., , 2010 Steidle et al., 2003; Mazer et al., 2005; Morgentaler et al., 2008; Swerdloff et al., 2015) .
Clinical experience has revealed remarkable inter-individual variability in serum testosterone levels in hypogonadal men treated with testosterone (Snyder & Lawrence, 1980; Meikle et al., 1996; Wang et al., 2000 Wang et al., , 2011 Bhasin et al., 2001; Steidle et al., 2003; Mazer et al., 2005; Morgentaler et al., 2008; Swerdloff et al., 2015) . This inter-individual variability in testosterone levels has been observed with all testosterone formulations (Snyder & Lawrence, 1980; Meikle et al., 1996; Wang et al., 2000 Wang et al., , 2011 Bhasin et al., 2001; Steidle et al., 2003; Mazer et al., 2005; Morgentaler et al., 2008; Swerdloff et al., 2015) , but the variability has been particularly striking with the transdermal testosterone gels (Swerdloff et al., 2015) . Hence, some hypogonadal men receiving testosterone therapy do not achieve optimum therapeutic effect because of suboptimal testosterone levels, while others whose serum testosterone levels rise into the supraphysiologic range might be rendered susceptible to adverse events, especially erythrocytosis. However, the participant-level factors (e.g., body weight, age, sex hormone-binding globulin (SHBG), and baseline testosterone) that might contribute to inter-individual variability in testosterone levels during testosterone therapy are incompletely understood; an understanding of these factors would be helpful to the clinicians in optimizing testosterone therapy.
The primary aim of this investigation was to characterize the participant-level factors that contribute to the variability in ontreatment testosterone levels during testosterone therapy. We used data from three randomized trials: the Testosterone in Older Men with Mobility Limitation (TOM) Trial (LeBrasseur et al., 2009; Basaria et al., 2010) , the Effects of Testosterone on Pain Perception (TAP) Trial (Basaria et al., 2015a) , and the Effects of Testosterone on Atherosclerosis Progression (TEAAM) Trial (Basaria et al., 2015b) . These three trials were selected because they recruited participants over a wide age range, used 1% transdermal testosterone gels (either Testim or 1% Androgel), and had testosterone levels measured 2-4 weeks after randomization for dose adjustment.
An exploratory hypothesis-generating aim was to determine whether polymorphisms in the genes encoding testosteronemetabolizing enzymes could explain the variation in on-treatment testosterone concentrations in a subset of men who were randomized to testosterone arm in the TOM Trial and in whom DNA was available for these analyses. The variability in serum testosterone concentrations on a fixed dose of transdermal testosterone could be due to variation in drug absorption into the blood stream or the inter-individual differences in plasma clearance of testosterone. Because the variability has been observed even in men treated with the injectable testosterone esters (Coviello et al., 2006; Swerdloff et al., 2015) , for which we assume 100% bioavailability, we infer that differences in circulating levels during testosterone therapy are in part due to genetic differences in plasma clearance of testosterone. Indeed, genetic differences in testosterone metabolism and clearance have been previously suggested (Santner et al., 1998; Wang et al., 2004; Schulze et al., 2008; Eriksson et al., 2009; Sten et al., 2009) . Therefore, this initial effort was focused on an exploratory analyses of candidate genes that are associated with testosterone's metabolism and clearance in a subset of participants of the TOM trial.
METHODS
All three randomized trials -The TOM Trial (LeBrasseur et al., 2009; Basaria et al., 2010) , the TAP Trial (Basaria et al., 2015a) , and the TEAAM Trial (Basaria et al., 2015b) -were reviewed and approved by the institutional review boards at Boston University Medical Center and Brigham and Women's Hospital. The study participants provided written informed consent. A subset of TOM Trial participants also signed a separate consent form for DNA collection for the pharmacogenetic study. The main findings of these trials have been published previously (LeBrasseur et al., 2009; Basaria et al., 2010 Basaria et al., , 2015a .
The included trials
The testosterone in older men with mobility limitations (TOM) trial
The TOM Trial was a placebo-controlled, randomized trial designed to determine the effects of testosterone administration on lower extremity strength and physical function in older men with mobility limitation and low total or free testosterone (LeBrasseur et al., 2009; Basaria et al., 2010) . The study consisted of a 24-week intervention followed by a 12-week observation period. Participants were men, ≥65 years old, with total testosterone 100-350 ng/dL or free testosterone <50 pg/mL in a sample drawn between 7 and 11 AM. The subjects were defined as mobility limited if they reported difficulty walking two blocks on a level surface or climbing ten steps and had Short Physical Performance Battery (SPPB) scores between 4 and 9 representing mild-to-moderate mobility limitation. Participants applied transdermal gel containing either placebo or 10-g gel containing 100-mg testosterone (Testim 1%, Auxilium Pharmaceuticals, Norristown, PA) daily for 6 months. Two weeks after randomization, testosterone levels were measured two and four hours after gel application. If average testosterone concentration was <500 ng/dL or >1000 ng/dL, the dose was increased to 15-g or reduced to 5-g. All subjects received three gel tubes daily in various combinations of placebo and testosterone to maintain blinding.
Testosterone's effects on atherosclerosis progression in aging men (TEAAM) trial
The TEAAM Trial aimed to determine the effects of testosterone administration on subclinical atherosclerosis progression, assessed using common carotid artery -intima media thickness using B mode ultrasound, and coronary artery calcium using multi-detector electron beam computerized scan (Basaria et al., 2015b) . The trial recruited 308 men, 60-75 years old, with total testosterone 100-400 ng/dL or free testosterone<50 pg/mL, who had no contraindication for testosterone administration. The participants were randomized to receive 7.5-g 1% testosterone or placebo gel daily for 3 years. The dose was adjusted based on serum testosterone levels measured between two and 12 h after gel application, 2 weeks after randomization to achieve testosterone levels in the target range of 500-900 ng/dL while maintaining blinding. If the total testosterone levels were <500 ng/dL or >900 ng/dL, the dose was either increased to 10-g or reduced to 5-g daily. The participants were then maintained on this dose for the remaining duration of the 3-year intervention period. The subjects recruited at the Boston site were included in this analysis.
The effects of testosterone replacement on pain sensitivity and pain tolerance in men with opioid-induced androgen deficiency: testosterone and pain (TAP) trial
The primary aim of the TAP Trial was to evaluate the effects of testosterone replacement on pain sensitivity and pain tolerance in men with opioid-induced hypogonadism (Basaria et al., 2015a) . This was a randomized, double blind, placebo-controlled, parallel armtrial in which hypogonadal men, 18-64 years, with chronic non-cancer pain who were on chronic opioids, and low serum testosterone levels (<350 ng/dL) were randomized to either 5 g of 1% transdermal testosterone gel (Androgel) or placebo gel daily for 14 weeks. The primary outcome was change in self-reported clinical pain and objectively assessed pain 152 Andrology, 2018, 6, 151-157 sensitivity. The target range for serum total testosterone level was between 500 and 1000 ng/dL. Two weeks after randomization, the dose was adjusted by an unblinded study physician; if total testosterone level was <500 ng/dL, the dose was increased to 7.5 g daily. For any subject in the testosterone group requiring a dose increase, the unblinded physician also assigned a (simulated) dose increase in a randomly selected subject in the placebo group, thus maintaining blinding.
Serum or plasma samples
Total testosterone level was measured 2 weeks after randomization, typically between 2 and 12 h after gel application. Total testosterone levels were measured in two blood samples drawn 2 h apart in the TOM and TEAAM trials.
Measurement of testosterone levels
Testosterone levels in TOM and TEAAM trials were measured at Quest Diagnostics, San Juan Capistrano, CA using Bayer Advia Centaur immunoassay that has been shown to have excellent correlation with liquid chromatography-tandem mass spectrometry (r 2 = 0.945) and sensitivity of 10 ng/dL (Salameh et al., 2010) . Testosterone levels in the TAP Trial were measured using LC-MS/MS assay with a functional sensitivity of 1 ng/dL .
Genotyping DNA and clinical data (baseline and 2 weeks) were available from 44 testosterone-treated subjects and 44 placebo-treated subjects from the TOM trial. Genomic DNA was extracted from peripheral blood lymphocytes by a CLIA certified laboratory using standard methodology.
Genotyping was performed using a custom Goldengate Assay from Illumina which included 1152 single nucleotide polymorphisms (SNPs) in genes involved in testosterone metabolism or genes that have been previously reported to be associated with testosterone levels (Table S1 ). The following criteria were used to select SNPs from the candidate genes: (i) minor allele frequency (MAF) >5% (ii) at least two SNPs per LD block (based on Caucasian data) (iii) all singleton SNPs not in LD blocks. In addition, the two androgen receptor trinucleotide repeats (CAG and GGC) and the copy number variation (CNV) in UGT2B17 were analyzed. Stringent genetic data quality control was performed for each patient sample and for each genetic marker. In brief, samples and genetic variants with call rates <90% were removed from analysis, and SNPs with <5 copies of the minor allele in the genotyped Caucasian population were excluded. Hardy-Weinberg equilibrium was checked within the Caucasian population and all variants with HWE p values <0.0001 were flagged but still analyzed. All patient samples and 951 of the 1152 variants passed quality control metrics and were included in the analysis.
Statistical analyses
The baseline characteristics of the participants were tabulated, and mean and standard deviations were computed for continuous variables and frequencies for categorical variables.
To elucidate the participant-level factors associated with variation in on-treatment testosterone concentrations during testosterone administration, we estimated the proportion of variance in change in testosterone levels accounted for by successive introduction of explanatory factors into multiple regression models. In these models, testosterone change was scaled according to the trial-specific daily dose of testosterone administered over this two-week period, such that the outcome was expressed as a difference per gram daily testosterone dose. Explanatory factors suggested by exploratory analyses and clinical import included age, baseline total testosterone and SHBG, height and weight, total body fat and nonfat mass by DEXA, hematocrit, and creatinine. Total variance in change in hormone levels explained was estimated using the coefficient of determination (R 2 ) evaluated with introduction of each successive explanatory variable. To accommodate missing data, we used multiple imputation by chained equations (MICE) (Azur et al., 2011) , with 50 imputations per missing data point, each allowed to converge over 50 iterations. Fixed relationships (e.g., that between total testosterone at baseline and two weeks and the scaled difference between them) were preserved within each imputation.
Genotyping data were available on 44 participants assigned to testosterone in the TOM trial. In these individuals, we considered the utility of two polymorphisms in the AKR1C3 (17b-hydroxysteroid dehydrogenase type 5 or 17b-HSD5) gene (rs12529 and rs10795245) in explaining additional variation in on-treatment testosterone levels. We made unadjusted comparisons between these participants and other TOM trial participants who did not have genotyping data using medians, interquartile intervals, and the Wilcoxon rank sum test. We then reconstructed the regression models described above including also those polymorphisms as explanatory factors, but restricted to the individuals on whom the genotyping was available.
All descriptive statistics are presented on participants with observed data; model-based estimates of R 2 are derived from the imputation procedure described above.
Analysis of the association of variation in on-treatment testosterone levels with candidate genotypes in the TOM trial The analysis was performed for each SNP using a Last Observation Carried Forward (LOCF) analysis of covariance (ANCOVA) model. The model included change in testosterone concentrations at week 2 as the dependent variable and baseline testosterone level, age, genotype, and genotype-by-treatment interaction as fixed effect covariates. Analysis was conducted using SAS PROC MIXED, and genotype effect within each treatment arm at week 2 was obtained through contrast statements. The ANCOVA model included fixed covariates of age, lean mass, and baseline levels of testosterone. The copy number variation (CNV) was treated like a SNP; 0 repeats vs. 1 repeat vs. 2 repeats. The CAG AR repeat analysis was represented by a discrete variable assuming three levels according to whether the number of repeats is less than or equal to 20 (≤20), between 21 and 26 (Benjamini & Hochberg, 1995; Wang et al., 2004; Salameh et al., 2010; Azur et al., 2011; Bhasin et al., 2011; Tsujimoto et al., 2016) or larger than or equal to 27 (≥27). Association between each of the variables of interest and the number of CAG repeats was evaluated by testing the null hypothesis that the fixed effect for all three levels of the CAG repeats (≤20, 21-26, ≥27) is equal.
RESULTS
The baseline characteristics of participants in the included trials are shown in Table 1 . Each of the trials had median BMI near 30 kg/m 2 . The differences in baseline testosterone levels are in part a reflection of the different eligibility testosterone thresholds for each trial. Figure 1 shows individual trajectories from baseline to two-week testosterone level for participants randomized to testosterone in each of the three trials, highlighting the observed variation in response. Variation at two weeks increased substantially with the initial daily testosterone dose (TAP, 5 g; TEAAM 7.5 g; TOM, 10 g). Table 2A ,B describe the distribution of twoweek testosterone values and change in testosterone levels from baseline to 2 weeks, respectively. The large variation in treatment response is illustrated by the large range of responses in each trial. A substantial fraction of participants in each trial failed to raise their serum testosterone levels above 400 ng/dL prior to dose adjustment [TAP 17 (47%); TEAAM 19 (38%); TOM 9 (9%)], with the observed pattern consistent with the trials' starting doses. A smaller fraction had on-treatment testosterone levels above 1000 ng/dL [(TAP 2 (6%); TEAAM 4 (8%); TOM 29 (30%)], and some even above 1200 ng/dL [(TAP 1 (3%); TEAAM 2 (4%); TOM 14 (14%)]. Even after dose adjustment, there was substantial variation in on-treatment levels at subsequent study visits in all trials (Fig. 2) . We evaluated the participant-level factors that might contribute to variation in testosterone levels. Table 3 provides the total variance accounted for (R 2 ) for a series of sequentially developed regression models for on-treatment testosterone and change in testosterone, respectively. In the TEAAM and TOM trials, these baseline participant characteristics individually accounted for only a small fraction of the overall variance in two-week change in testosterone levels (approximately 8%). They were somewhat more successful in accounting for said variation in the TAP trial, which enrolled younger men at a smaller starting dose, but even there the vast majority of variation remained unexplained (R 2 = 29%).
In the TOM trial, when the model was restricted to participants whose AKR1C3 genotype was known (N = 44), the 13 participants exhibiting the AKR1C3 C/C genotype at rs12529 had greater two-week increased testosterone than those who did not [median (interquartile interval) 761 (507 to 1187) vs. 396 (219 to 598); p = 0.009 by Wilcoxon test]. The six participants with the greatest absolute change in testosterone, and eight of the ten with the greatest change, exhibited the C/C genotype for this polymorphism. Among this group of 44 participants, the explanatory factors considered were more successful in accounting for variation in two-week testosterone change, but again the bulk of variation was unexplained (R 2 = 24%) than they had been when considering all 106 TOM participants (R 2 = 8%) (Table 3) . However, with the introduction of the AKR1C3 polymorphism, model fit was substantially improved (R 2 = 43%), such that the proportion of variation accounted for by the polymorphism was nearly as great as that accounted for by all other factors combined.
Results of the genotype analyses
A total of 951 variants were included in the genetic analysis (Table S1 ). To minimize the loss of statistical power, the statistical analyses were prioritized as follows. The primary analysis included 49 variants (all variants in SHGB, UGT2B7, UGT2B15, and UGT2B17) and the exploratory analysis included 902 variants (all variants not analyzed in primary objective). There were no significant clinical or demographic differences between patients in the genetic cohort and the overall cohort.
Of the 49 SNPs included in the primary analysis, two SNPs had uncorrected p values <0.05, and both were in SHBG (Tables S2  and S3 ), none of the p values remained significant after multiple testing correction. Rs9282846 had only one subject who is heterozygous for the minor allele, making this result suspect.
In the exploratory analysis, 47 of 902 variants had uncorrected p values <0.05 (Table S2 ). These 47 variants were then analyzed in a dichotomous analysis to assess whether they were associated with high levels of testosterone; 16/17 of the variants that were also significant in the dichotomous analysis are in LD within the AKR1C3 gene (Table S2 ). For AKR1C3 SNP rs12529, five of six subjects were homozygous for the major genotype CC, and the sixth subject was homozygous for the minor genotype GG (Table 4 ). The number of subjects with T levels ≥1050 ng/dL is enriched (83%) in the homozygous CC genotype. Thus, the variants in AKR1C3 are suggestively associated with on-treatment testosterone levels in continuous and dichotomous analyses.
The HSD17B3 genetic variant was not very informative. This SNP was significant in the dichotomous analysis because of the heterozygous subjects: no subjects heterozygous for this variant had testosterone levels ≥1050 ng/dL, yet 66% of subjects with testosterone levels <1050 ng/dL were heterozygous. The result is most likely a false positive.
Subjects with the medium CAG tract length in exon 1 of the androgen receptor had higher on-treatment testosterone levels than those with shorter or longer CAG tracts (Effect size 116, CI 16 to 214, p < 0.001) .
DISCUSSION
These analyses of data from three randomized testosterone trials of 1% transdermal testosterone gels highlight the substantial variation in on-treatment testosterone levels in men who were participating in randomized trials of testosterone and were assigned to testosterone arms of these trials. A substantial fraction of men receiving 5, 7.5, or 10 g of 1% testosterone transdermal gel daily had testosterone levels below 400 ng/dL and some even below 300 ng/dL. Even more concerning is the fact that a small fraction had levels above 1000 ng/dL. The increase in testosterone levels from baseline for each gram of the 1% transdermal gel also varied substantially across participants in each of the three trials. Thus, these data further support for the recommendation of the Endocrine Society guidelines to monitor on-treatment testosterone levels and perform appropriate dose adjustments to maintain testosterone levels within the target range . Even after dose adjustment, the on-treatment testosterone levels varied substantially, and a significant fraction of participants had testosterone levels outside the study's target range and outside the physiologic range of testosterone levels in healthy men. There was poor correlation and concordance among on-treatment testosterone levels post-dose adjustment. Consistent with the results of other trials (Swerdloff et al., 2015) , these data suggest that multiple dose adjustments may be required to achieve and maintain testosterone levels in the desired target range in men receiving testosterone therapy.
The participant-level factors, which can be easily ascertained in clinical practice, such as the age, body size, initial testosterone 
Time since randomization (weeks)
Serum total testosterone at baseline and two weeks (ng/dL) Figure 1 Each subject's absolute circulating total testosterone level (ng/dL) at baseline (time 0) and at 2 weeks after randomization is shown via a line segment. The 2-week levels represent on-treatment levels two weeks after randomization to the testosterone arm of each of the three trials. The two-week levels were drawn 2 to 8 h after application of the testosterone gel. To convert testosterone concentrations from ng/dL to SI units (nmol/L), multiply concentrations in ng/ dL by 0.0347. Standard deviation  52  44  53  25th percentile  11  8  34  50th percentile  32  27  56  75th percentile  65  60  79 Serum testosterone levels are ng/dL. To convert to SI units (nmol/L), multiply concentrations in ng/dL by 0.347. TAP, testosterone and pain (TAP) trial; TEAAM, testosterone's effects on atherosclerosis progression in aging men trial; TOM, the effects of testosterone in older men with mobility limitation trial. 2 is given for a model including independent variables listed in that row as well as all rows previous. For instance, the third row refers to models that include height, weight, total testosterone, SHBG, and age as independent ('predictor') variables. Figure 2 Serum total testosterone levels at baseline, middle (week 6 in the TAP Trial, week 12 in the TOM Trial, and month 18 in TEAAM Trial), and at the end of the treatment period (week 12 in the TAP Trial, month 6 in TOM Trial, and month 36 in the TEAAM Trial). All men were initially randomized to receive a fixed starting dose of testosterone (5 g in TAP, 7.5 g in TEAAM, and 10 g in the TOM Trial). The dose was adjusted in a blinded manner based on week 2 on-treatment testosterone levels and maintained constant for the rest of the duration of each trial. The variability in serum testosterone levels in samples drawn during mid-treatment visit and at the end of treatment in spite of dose adjustment at week 2 is apparent.
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level, and SHBG levels accounted for only a small fraction of the variation in on-treatment testosterone levels. Previous studies using injectable testosterone esters have shown a significant age effect on apparent plasma clearance of testosterone and higher testosterone levels in older men than in young men (Coviello et al., 2006) . In the three trials included in this study, age was not strongly correlated with change in testosterone levels from baseline. It is possible that the variation in transdermal absorption contributed a substantially greater fraction of the overall variation in on-treatment testosterone levels than age and other participant-level factors so that the overall contribution of age, body size, baseline testosterone levels, and SHBG to the overall variation was relatively small. Several caveats should be considered. The starting daily doses of testosterone gel in various trials varied from 5 to 10 g. The increments in testosterone for each g of testosterone gel also showed high level of variation. Two different transdermal gels were used -the 1% Testim gel in the TOM trials, and the 1% Androgel in the TAP and TEAAM trials. Generally, similar high level of variation was observed with either type of testosterone gel. Although the actual time of blood draw differed, the blood was drawn within 2 and 8 h after gel application in all the studies, as recommended by the Endocrine Society guideline. The testosterone levels were measured using an LC-MS/MS assay in the TAP trial, and by an immunoassay that has been validated against LC-MS/MS in the TOM and TEAAM trial, reflecting the earlier time period of trial initiation for the latter two trials when LC-MS/ MS assays were not available; the coefficients of variations of the assays were small relative to the on-treatment variation in testosterone levels. We did not record the foods eaten or the exercise patterns, which can affect testosterone metabolism (CadouxHudson et al., 1985; Tsujimoto et al., 2016) .
Exploratory genotype association analyses using a candidate gene approach suggested that the polymorphisms in the SHBG gene may be associated with on-treatment testosterone levels. This hypothesis seems plausible because polymorphisms in SHBG gene have been previously associated with populationlevel variation in testosterone levels in men (Ohlsson et al., 2011) . Another interesting finding of these exploratory analyses is that the subjects homozygous for the major AKR1C3 genotype had higher on-treatment testosterone levels, and 83% of men who had on-treatment levels above 1050 ng/dL were homozygous for the major genotype. The AKR1C3 variant rs12529 that was significant in both continuous and dichotomous analyses results in a non-conservative amino acid change (H5Q). This variant is a promoter and/or enhancer of androgen receptor in a number of cells and a number of proteins including POL2, TAF1, P300, SP1, KAP1, GTF2F1, TBP, CFOS, and GATA1 bind to this polymorphic site. The functional significance of this polymorphism in the AKRC3 gene remains to be investigated in larger studies. Further studies should assess the association of SHBG polymorphisms and AKR1C3 variants with the variation in ontreatment testosterone levels and determine whether these genetic variants are associated with increased risk of adverse events due to high on-treatment testosterone levels.
In summary, testosterone therapy using transdermal gels in men with low or low normal testosterone levels is associated with substantial variation in on-treatment testosterone levels, which is only partly explained by participant-level factors. Our data support the Endocrine Society guideline that multiple dose adjustments are needed to maintain serum testosterone levels within the desired target range in men receiving testosterone transdermal gels. Further studies are needed to confirm the association of SHBG polymorphisms and AKR1C3 variants with the variation in on-treatment testosterone levels and determine whether these genetic variants are associated with increased risk of adverse events due to high on-treatment testosterone levels.
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